Spasticity complicating metrizamide myelography.
Temporary but considerable increase in spasticity following myelography using metrizamide at 300 mgs I/ml concentration occurred in 4 patients. In 3 of the patients the diagnosis is uncertain, but it is likely to be some form of degenerative disease involving motor pathways in two of them; the fourth case has cervical spondylotic myelopathy. The spasticity might be related to the anticholinesterase activity of metrizamide or to competitive inhibition of endogenous glucose metabolism by the deoxyglucose component of the metrizamide molecule.
D005260:Female; D006801:Humans; D008297:Male; D008793:Metrizamide / Q000009:adverse effects*; D008875:Middle Aged; D009128:Muscle Spasticity / Q000209:etiology*; D009192:Myelography / Q000009:adverse effects*
D008793:Metrizamide